Scutellarin ameliorates osteoarthritis by protecting chondrocytes and subchondral bone microstructure by inactivating NF-κB/MAPK signal transduction - 18/10/22
, Kai Zhang a, b, ⁎ , Hui Ma a, b, ⁎ Abstract |
Osteoarthritis (OA), a chronic degenerative disease, is a major cause of pain, disability, and reduced quality of life among the elderly worldwide. The key to treating it is early prevention and effective intervention. The anti-inflammatory effects of scutellarin (SCU), a flavonoid derived from Erigeron breviscapus, have been increasingly reported. However, the mechanism by which SCU affects OA remains unclear. This study aimed to investigate the therapeutic effects and potential molecular mechanisms of SCU in the development of OA. Here, we found that SCU inhibited interleukin (IL)− 1β-induced degradation of the extracellular matrix (ECM) of cartilage through the NF-kappaB/mitogen-activated protein kinases (NF-κB/MAPK) signaling pathway. In addition, in vivo data showed that SCU significantly reduced cartilage damage in the destabilization of the medial meniscus (DMM) mouse model and ovariectomy (OVX)-induced subchondral bone loss and cartilage degeneration in mice. In summary, our data showed that SCU is expected to become a potentially effective candidate treatment strategy for OA.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Scutellarin alleviates the microstructural damage of subchondral bone and ameliorates articular cartilage degeneration in OVX mice. |
• | Scutellarin regulates the expression of p-P65 and p-P38 and alleviates IL-1β induced ECM disorder in ATDC5 cells. |
• | Scutellarin might ameliorate osteoarthritis by inactivating NF-κB/MAPK signal transduction. |
Abbreviations : ADAMTS, CCK-8, COL2A1, DMM, DAPI, DMEM, ECM, FBS, H&E, IL-1β, MAPK, MMPs, NF-κB, OA, OVX, OARSI, OD, PBS, p-JNK, p-P38, p-ERK, PVDF, SCU, S&F, TRAP
Keywords : Scutellarin, Osteoarthritis, Chondrocytes, Subchondral bone, NF-κB, MAPK
Plan
Vol 155
Article 113781- novembre 2022 Retour au numéro
Article précédent
- Characterization of the activity and the mechanism of action of a new toluquinol derivative with improved potential as an antiangiogenic drug
- José Antonio Torres-Vargas, Iván Cheng-Sánchez, Beatriz Martínez-Poveda, Miguel Ángel Medina, Francisco Sarabia, Melissa García-Caballero, Ana R. Quesada
- Novel microporous resin-based polymer device for sustained glipizide release: Production, characterization and pharmacokinetic study
- Haofan Liu, Bingwen Zhang, Yanna Chen, Zhe Cui, Liandong Hu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?